THANK YOU FOR SUBSCRIBING
Medical Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
Hugo is a multi-quadrant platform for soft tissue treatments that combines wristed tools, 3D imaging, and Medtronic's cloud-based surgical video capture and administration technology, Touch Surgery Enterprise
FREMONT, CA: Medtronic (NYSE:MDT) announced that its Hugo robotic-assisted surgery system successfully completed its first clinical procedure in Europe. The robotic prostatectomy was performed by Dr. Alexandre Mottrie, chief of urology at OLV Hospital in Aalst, Belgium. Mottrie is also the creator and CEO of the ORSI Academy in Belgium, which provides training, research, and data analysis to improve minimally invasive surgery best practices.
In a press statement, Mottrie commented, saying that performing Europe's very first procedure using the Hugo RAS system was a career milestone for him. He also expressed that he was intimately aware of the constraints that withheld the benefits of surgical robotics from physicians, hospitals, and patients for more than two decades. He believes they are now entering a new era of increased accessibility and flexibility.
Hugo is a multi-quadrant platform for soft tissue treatments that combines wristed tools, 3D imaging, and Medtronic's cloud-based surgical video capture and administration technology, Touch Surgery Enterprise. Over the last year, Medtronic has announced the first urologic and gynecologic surgeries with Hugo in Latin America and Asia-Pacific, with the first patient surgery scheduled for June 2021 in Chile. Clinical data from these operations and cases, which are now being undertaken in Europe, will be used to support regulatory applications around the world.
Hugo has a medical device authorization in Canada, as well as Australian clearance, in addition to the CE mark. It is still an experimental device that is not available for purchase in the United States. Megan Rosengarten, president of Medtronic's surgical robotics division, stated that this is an exciting and crucial moment for healthcare in Europe, and they are happy to share it with Dr. Mottrie and the team at OLV. Over the many years they have worked together, Dr. Mottrie has left an indelible impact on their programme, and now, owing to their cooperation with OLV, Medtronic's mission to provide the benefits of robotic-assisted surgery to more patients in Europe is well underway.
Read Also
